Effect of BRCA1 and XPG mutations on treatment response to trabectedin and pegylated liposomal doxorubicin in patients with advanced ovarian cancer: exploratory analysis of the phase 3 OVA-301 study
In this exploratory analysis, patients with recurrent ovarian cancer carrying BRCA1mut gene had improved outcomes with trabectedin + PLD treatment compared with PLD alone. Prospective evaluation of BRCA status is likely an important evaluation for DNA-damaging agents and may significantly impact int...
Gespeichert in:
| Veröffentlicht in: | Annals of oncology 2015-05, Vol.26 (5), p.914-920 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 920 |
|---|---|
| container_issue | 5 |
| container_start_page | 914 |
| container_title | Annals of oncology |
| container_volume | 26 |
| creator | Monk, B.J. Ghatage, P. Parekh, T. Henitz, E. Knoblauch, R. Matos-Pita, A.S. Nieto, A. Park, Y.C. Cheng, P.S. Li, W. Favis, R. Ricci, D. Poveda, A. |
| description | In this exploratory analysis, patients with recurrent ovarian cancer carrying BRCA1mut gene had improved outcomes with trabectedin + PLD treatment compared with PLD alone. Prospective evaluation of BRCA status is likely an important evaluation for DNA-damaging agents and may significantly impact interpretation of clinical studies. XPG may be a biomarker of poor outcome in these patients.
We investigated the association of BRCA1 and XPG mutations with response rate (RR), progression-free survival (PFS) and overall survival (OS) in a subset of patients from a phase 3 clinical trial comparing the efficacy and safety of trabectedin + pegylated liposomal doxorubicin (PLD) versus PLD alone in patients with recurrent ovarian cancer.
A candidate array was designed based on the Breast Cancer Information Core database for BRCA mutation analyses. An exploratory analysis of BRCA1/XPG mutation status was conducted using a two-sided log-rank test and 0.05 significance in germline DNA samples from 264 women with failed first-line platinum-based chemotherapy, randomized (1 : 1) to trabectedin + PLD or PLD alone.
Overall, 41 (16%) of the 264 women had BRCA1mut (trabectedin + PLD: n = 24/135, 18%; PLD: n = 17/129; 13%) and 17 (6%) had XPGmut (trabectedin + PLD: n = 8/135, 6%; PLD: n = 9/129, 7%). A higher RR was observed in BRCA1mut patients (20/41; 49%) versus BRCA1wt patients (62/223; 28%). Within the BRCA1mut group, trabectedin + PLD-treated patients had longer PFS and longer OS than PLD-treated patients (median PFS 13.5 versus 5.5 months, P = 0.0002; median OS 23.8 versus 12.5 months, P = 0.0086), whereas in BRCA1wt patients, OS was not significantly different (median OS: 19.1 versus 19.3 months; P = 0.9377). There were no differences in OS or PFS of patients with XPGmut between the two treatment arms. However, trabectedin + PLD-treated patients with XPGmut had a trend toward shorter PFS (median PFS: 1.9 versus 7.5 months; P = 0.1666) and OS (median OS: 14.5 versus 20.7 months; P = 0.1774) than those with XPGwt.
In this exploratory analysis, patients with recurrent ovarian cancer carrying the BRCA1mut had improved outcomes with trabectedin + PLD treatment compared with PLD alone. Prospective evaluation of BRCA status is likely an important evaluation for DNA-damaging agents and may significantly impact interpretation of clinical studies. XPG may be a biomarker of poor outcome in these patients. |
| doi_str_mv | 10.1093/annonc/mdv071 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1819136124</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0923753419315133</els_id><sourcerecordid>1819136124</sourcerecordid><originalsourceid>FETCH-LOGICAL-c413t-a4e5d5bc7e1a2096cf9f9879333816f6ce3b2c31b5f9806b851fdd364f6a26343</originalsourceid><addsrcrecordid>eNqNkUFv1DAQhSMEokvhyBX5yCXUjhMn5ras2oJUqQgB4hY59pg1SuxgO0vzB_ldzLKFGxKSLWtG37yx3iuK54y-YlTyC-V98PpiMgfasgfFhjVClh2t2cNiQ2XFy7bh9VnxJKVvlFIhK_m4OKuatqp4RzfFz0trQWcSLHnzYbdlRHlDvry_JtOSVXbBJxI8yRFUnsBnEiHN2ASSA3bVgLNgnP89NsPXdVRYk9HNIYVJjcSEuxCXwWlk8MyoiTKJ_HB5T5Q5KK-RDwcVnfJEH8v4msDdPIaocogrKqtxTS4dv5j3QOa9wvWc3H7elpwykvJi1qfFI6vGBM_u3_Pi09Xlx93b8ub2-t1ue1PqmvFcqhoa0wy6BaYqKoW20squlZzzjgkrNPCh0pwNDbapGLqGWWO4qK1QleA1Py9ennTnGL4vkHI_uaRhHJWHsKSedUwyLlj1H6hoG7ycUUTLE6pjSCmC7efoJhXXntH-mHJ_Srk_pYz8i3vpZZjA_KX_xIpAewIAvTg4iH3S6Dta7SIm1pvg_iH9C9hDu5Y</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1675167310</pqid></control><display><type>article</type><title>Effect of BRCA1 and XPG mutations on treatment response to trabectedin and pegylated liposomal doxorubicin in patients with advanced ovarian cancer: exploratory analysis of the phase 3 OVA-301 study</title><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Alma/SFX Local Collection</source><creator>Monk, B.J. ; Ghatage, P. ; Parekh, T. ; Henitz, E. ; Knoblauch, R. ; Matos-Pita, A.S. ; Nieto, A. ; Park, Y.C. ; Cheng, P.S. ; Li, W. ; Favis, R. ; Ricci, D. ; Poveda, A.</creator><creatorcontrib>Monk, B.J. ; Ghatage, P. ; Parekh, T. ; Henitz, E. ; Knoblauch, R. ; Matos-Pita, A.S. ; Nieto, A. ; Park, Y.C. ; Cheng, P.S. ; Li, W. ; Favis, R. ; Ricci, D. ; Poveda, A.</creatorcontrib><description>In this exploratory analysis, patients with recurrent ovarian cancer carrying BRCA1mut gene had improved outcomes with trabectedin + PLD treatment compared with PLD alone. Prospective evaluation of BRCA status is likely an important evaluation for DNA-damaging agents and may significantly impact interpretation of clinical studies. XPG may be a biomarker of poor outcome in these patients.
We investigated the association of BRCA1 and XPG mutations with response rate (RR), progression-free survival (PFS) and overall survival (OS) in a subset of patients from a phase 3 clinical trial comparing the efficacy and safety of trabectedin + pegylated liposomal doxorubicin (PLD) versus PLD alone in patients with recurrent ovarian cancer.
A candidate array was designed based on the Breast Cancer Information Core database for BRCA mutation analyses. An exploratory analysis of BRCA1/XPG mutation status was conducted using a two-sided log-rank test and 0.05 significance in germline DNA samples from 264 women with failed first-line platinum-based chemotherapy, randomized (1 : 1) to trabectedin + PLD or PLD alone.
Overall, 41 (16%) of the 264 women had BRCA1mut (trabectedin + PLD: n = 24/135, 18%; PLD: n = 17/129; 13%) and 17 (6%) had XPGmut (trabectedin + PLD: n = 8/135, 6%; PLD: n = 9/129, 7%). A higher RR was observed in BRCA1mut patients (20/41; 49%) versus BRCA1wt patients (62/223; 28%). Within the BRCA1mut group, trabectedin + PLD-treated patients had longer PFS and longer OS than PLD-treated patients (median PFS 13.5 versus 5.5 months, P = 0.0002; median OS 23.8 versus 12.5 months, P = 0.0086), whereas in BRCA1wt patients, OS was not significantly different (median OS: 19.1 versus 19.3 months; P = 0.9377). There were no differences in OS or PFS of patients with XPGmut between the two treatment arms. However, trabectedin + PLD-treated patients with XPGmut had a trend toward shorter PFS (median PFS: 1.9 versus 7.5 months; P = 0.1666) and OS (median OS: 14.5 versus 20.7 months; P = 0.1774) than those with XPGwt.
In this exploratory analysis, patients with recurrent ovarian cancer carrying the BRCA1mut had improved outcomes with trabectedin + PLD treatment compared with PLD alone. Prospective evaluation of BRCA status is likely an important evaluation for DNA-damaging agents and may significantly impact interpretation of clinical studies. XPG may be a biomarker of poor outcome in these patients.</description><identifier>ISSN: 0923-7534</identifier><identifier>EISSN: 1569-8041</identifier><identifier>DOI: 10.1093/annonc/mdv071</identifier><identifier>PMID: 25722380</identifier><language>eng</language><publisher>England: Elsevier Ltd</publisher><subject>Aged ; Antibiotics, Antineoplastic - adverse effects ; Antibiotics, Antineoplastic - therapeutic use ; Antineoplastic Agents, Alkylating - adverse effects ; Antineoplastic Agents, Alkylating - therapeutic use ; Antineoplastic Combined Chemotherapy Protocols - adverse effects ; Antineoplastic Combined Chemotherapy Protocols - therapeutic use ; BRCA1 ; BRCA1 Protein - genetics ; Dioxoles - adverse effects ; Dioxoles - therapeutic use ; Disease Progression ; Disease-Free Survival ; DNA-Binding Proteins - genetics ; Doxorubicin - adverse effects ; Doxorubicin - analogs & derivatives ; Doxorubicin - therapeutic use ; Endonucleases - genetics ; Female ; Humans ; Middle Aged ; Mutation ; Neoplasm Recurrence, Local ; Nuclear Proteins - genetics ; Ovarian Neoplasms - drug therapy ; Ovarian Neoplasms - genetics ; Ovarian Neoplasms - mortality ; Ovarian Neoplasms - pathology ; pegylated liposomal doxorubicin ; Pharmacogenetics ; Polyethylene Glycols - adverse effects ; Polyethylene Glycols - therapeutic use ; recurrent ovarian cancer ; Tetrahydroisoquinolines - adverse effects ; Tetrahydroisoquinolines - therapeutic use ; Time Factors ; Trabectedin ; Transcription Factors - genetics ; Treatment Outcome ; XPG</subject><ispartof>Annals of oncology, 2015-05, Vol.26 (5), p.914-920</ispartof><rights>2015 European Society for Medical Oncology</rights><rights>The Author 2015. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: journals.permissions@oup.com.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c413t-a4e5d5bc7e1a2096cf9f9879333816f6ce3b2c31b5f9806b851fdd364f6a26343</citedby><cites>FETCH-LOGICAL-c413t-a4e5d5bc7e1a2096cf9f9879333816f6ce3b2c31b5f9806b851fdd364f6a26343</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27903,27904</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/25722380$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Monk, B.J.</creatorcontrib><creatorcontrib>Ghatage, P.</creatorcontrib><creatorcontrib>Parekh, T.</creatorcontrib><creatorcontrib>Henitz, E.</creatorcontrib><creatorcontrib>Knoblauch, R.</creatorcontrib><creatorcontrib>Matos-Pita, A.S.</creatorcontrib><creatorcontrib>Nieto, A.</creatorcontrib><creatorcontrib>Park, Y.C.</creatorcontrib><creatorcontrib>Cheng, P.S.</creatorcontrib><creatorcontrib>Li, W.</creatorcontrib><creatorcontrib>Favis, R.</creatorcontrib><creatorcontrib>Ricci, D.</creatorcontrib><creatorcontrib>Poveda, A.</creatorcontrib><title>Effect of BRCA1 and XPG mutations on treatment response to trabectedin and pegylated liposomal doxorubicin in patients with advanced ovarian cancer: exploratory analysis of the phase 3 OVA-301 study</title><title>Annals of oncology</title><addtitle>Ann Oncol</addtitle><description>In this exploratory analysis, patients with recurrent ovarian cancer carrying BRCA1mut gene had improved outcomes with trabectedin + PLD treatment compared with PLD alone. Prospective evaluation of BRCA status is likely an important evaluation for DNA-damaging agents and may significantly impact interpretation of clinical studies. XPG may be a biomarker of poor outcome in these patients.
We investigated the association of BRCA1 and XPG mutations with response rate (RR), progression-free survival (PFS) and overall survival (OS) in a subset of patients from a phase 3 clinical trial comparing the efficacy and safety of trabectedin + pegylated liposomal doxorubicin (PLD) versus PLD alone in patients with recurrent ovarian cancer.
A candidate array was designed based on the Breast Cancer Information Core database for BRCA mutation analyses. An exploratory analysis of BRCA1/XPG mutation status was conducted using a two-sided log-rank test and 0.05 significance in germline DNA samples from 264 women with failed first-line platinum-based chemotherapy, randomized (1 : 1) to trabectedin + PLD or PLD alone.
Overall, 41 (16%) of the 264 women had BRCA1mut (trabectedin + PLD: n = 24/135, 18%; PLD: n = 17/129; 13%) and 17 (6%) had XPGmut (trabectedin + PLD: n = 8/135, 6%; PLD: n = 9/129, 7%). A higher RR was observed in BRCA1mut patients (20/41; 49%) versus BRCA1wt patients (62/223; 28%). Within the BRCA1mut group, trabectedin + PLD-treated patients had longer PFS and longer OS than PLD-treated patients (median PFS 13.5 versus 5.5 months, P = 0.0002; median OS 23.8 versus 12.5 months, P = 0.0086), whereas in BRCA1wt patients, OS was not significantly different (median OS: 19.1 versus 19.3 months; P = 0.9377). There were no differences in OS or PFS of patients with XPGmut between the two treatment arms. However, trabectedin + PLD-treated patients with XPGmut had a trend toward shorter PFS (median PFS: 1.9 versus 7.5 months; P = 0.1666) and OS (median OS: 14.5 versus 20.7 months; P = 0.1774) than those with XPGwt.
In this exploratory analysis, patients with recurrent ovarian cancer carrying the BRCA1mut had improved outcomes with trabectedin + PLD treatment compared with PLD alone. Prospective evaluation of BRCA status is likely an important evaluation for DNA-damaging agents and may significantly impact interpretation of clinical studies. XPG may be a biomarker of poor outcome in these patients.</description><subject>Aged</subject><subject>Antibiotics, Antineoplastic - adverse effects</subject><subject>Antibiotics, Antineoplastic - therapeutic use</subject><subject>Antineoplastic Agents, Alkylating - adverse effects</subject><subject>Antineoplastic Agents, Alkylating - therapeutic use</subject><subject>Antineoplastic Combined Chemotherapy Protocols - adverse effects</subject><subject>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</subject><subject>BRCA1</subject><subject>BRCA1 Protein - genetics</subject><subject>Dioxoles - adverse effects</subject><subject>Dioxoles - therapeutic use</subject><subject>Disease Progression</subject><subject>Disease-Free Survival</subject><subject>DNA-Binding Proteins - genetics</subject><subject>Doxorubicin - adverse effects</subject><subject>Doxorubicin - analogs & derivatives</subject><subject>Doxorubicin - therapeutic use</subject><subject>Endonucleases - genetics</subject><subject>Female</subject><subject>Humans</subject><subject>Middle Aged</subject><subject>Mutation</subject><subject>Neoplasm Recurrence, Local</subject><subject>Nuclear Proteins - genetics</subject><subject>Ovarian Neoplasms - drug therapy</subject><subject>Ovarian Neoplasms - genetics</subject><subject>Ovarian Neoplasms - mortality</subject><subject>Ovarian Neoplasms - pathology</subject><subject>pegylated liposomal doxorubicin</subject><subject>Pharmacogenetics</subject><subject>Polyethylene Glycols - adverse effects</subject><subject>Polyethylene Glycols - therapeutic use</subject><subject>recurrent ovarian cancer</subject><subject>Tetrahydroisoquinolines - adverse effects</subject><subject>Tetrahydroisoquinolines - therapeutic use</subject><subject>Time Factors</subject><subject>Trabectedin</subject><subject>Transcription Factors - genetics</subject><subject>Treatment Outcome</subject><subject>XPG</subject><issn>0923-7534</issn><issn>1569-8041</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2015</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqNkUFv1DAQhSMEokvhyBX5yCXUjhMn5ras2oJUqQgB4hY59pg1SuxgO0vzB_ldzLKFGxKSLWtG37yx3iuK54y-YlTyC-V98PpiMgfasgfFhjVClh2t2cNiQ2XFy7bh9VnxJKVvlFIhK_m4OKuatqp4RzfFz0trQWcSLHnzYbdlRHlDvry_JtOSVXbBJxI8yRFUnsBnEiHN2ASSA3bVgLNgnP89NsPXdVRYk9HNIYVJjcSEuxCXwWlk8MyoiTKJ_HB5T5Q5KK-RDwcVnfJEH8v4msDdPIaocogrKqtxTS4dv5j3QOa9wvWc3H7elpwykvJi1qfFI6vGBM_u3_Pi09Xlx93b8ub2-t1ue1PqmvFcqhoa0wy6BaYqKoW20squlZzzjgkrNPCh0pwNDbapGLqGWWO4qK1QleA1Py9ennTnGL4vkHI_uaRhHJWHsKSedUwyLlj1H6hoG7ycUUTLE6pjSCmC7efoJhXXntH-mHJ_Srk_pYz8i3vpZZjA_KX_xIpAewIAvTg4iH3S6Dta7SIm1pvg_iH9C9hDu5Y</recordid><startdate>201505</startdate><enddate>201505</enddate><creator>Monk, B.J.</creator><creator>Ghatage, P.</creator><creator>Parekh, T.</creator><creator>Henitz, E.</creator><creator>Knoblauch, R.</creator><creator>Matos-Pita, A.S.</creator><creator>Nieto, A.</creator><creator>Park, Y.C.</creator><creator>Cheng, P.S.</creator><creator>Li, W.</creator><creator>Favis, R.</creator><creator>Ricci, D.</creator><creator>Poveda, A.</creator><general>Elsevier Ltd</general><scope>6I.</scope><scope>AAFTH</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>7U7</scope><scope>C1K</scope></search><sort><creationdate>201505</creationdate><title>Effect of BRCA1 and XPG mutations on treatment response to trabectedin and pegylated liposomal doxorubicin in patients with advanced ovarian cancer: exploratory analysis of the phase 3 OVA-301 study</title><author>Monk, B.J. ; Ghatage, P. ; Parekh, T. ; Henitz, E. ; Knoblauch, R. ; Matos-Pita, A.S. ; Nieto, A. ; Park, Y.C. ; Cheng, P.S. ; Li, W. ; Favis, R. ; Ricci, D. ; Poveda, A.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c413t-a4e5d5bc7e1a2096cf9f9879333816f6ce3b2c31b5f9806b851fdd364f6a26343</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2015</creationdate><topic>Aged</topic><topic>Antibiotics, Antineoplastic - adverse effects</topic><topic>Antibiotics, Antineoplastic - therapeutic use</topic><topic>Antineoplastic Agents, Alkylating - adverse effects</topic><topic>Antineoplastic Agents, Alkylating - therapeutic use</topic><topic>Antineoplastic Combined Chemotherapy Protocols - adverse effects</topic><topic>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</topic><topic>BRCA1</topic><topic>BRCA1 Protein - genetics</topic><topic>Dioxoles - adverse effects</topic><topic>Dioxoles - therapeutic use</topic><topic>Disease Progression</topic><topic>Disease-Free Survival</topic><topic>DNA-Binding Proteins - genetics</topic><topic>Doxorubicin - adverse effects</topic><topic>Doxorubicin - analogs & derivatives</topic><topic>Doxorubicin - therapeutic use</topic><topic>Endonucleases - genetics</topic><topic>Female</topic><topic>Humans</topic><topic>Middle Aged</topic><topic>Mutation</topic><topic>Neoplasm Recurrence, Local</topic><topic>Nuclear Proteins - genetics</topic><topic>Ovarian Neoplasms - drug therapy</topic><topic>Ovarian Neoplasms - genetics</topic><topic>Ovarian Neoplasms - mortality</topic><topic>Ovarian Neoplasms - pathology</topic><topic>pegylated liposomal doxorubicin</topic><topic>Pharmacogenetics</topic><topic>Polyethylene Glycols - adverse effects</topic><topic>Polyethylene Glycols - therapeutic use</topic><topic>recurrent ovarian cancer</topic><topic>Tetrahydroisoquinolines - adverse effects</topic><topic>Tetrahydroisoquinolines - therapeutic use</topic><topic>Time Factors</topic><topic>Trabectedin</topic><topic>Transcription Factors - genetics</topic><topic>Treatment Outcome</topic><topic>XPG</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Monk, B.J.</creatorcontrib><creatorcontrib>Ghatage, P.</creatorcontrib><creatorcontrib>Parekh, T.</creatorcontrib><creatorcontrib>Henitz, E.</creatorcontrib><creatorcontrib>Knoblauch, R.</creatorcontrib><creatorcontrib>Matos-Pita, A.S.</creatorcontrib><creatorcontrib>Nieto, A.</creatorcontrib><creatorcontrib>Park, Y.C.</creatorcontrib><creatorcontrib>Cheng, P.S.</creatorcontrib><creatorcontrib>Li, W.</creatorcontrib><creatorcontrib>Favis, R.</creatorcontrib><creatorcontrib>Ricci, D.</creatorcontrib><creatorcontrib>Poveda, A.</creatorcontrib><collection>ScienceDirect Open Access Titles</collection><collection>Elsevier:ScienceDirect:Open Access</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>Toxicology Abstracts</collection><collection>Environmental Sciences and Pollution Management</collection><jtitle>Annals of oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Monk, B.J.</au><au>Ghatage, P.</au><au>Parekh, T.</au><au>Henitz, E.</au><au>Knoblauch, R.</au><au>Matos-Pita, A.S.</au><au>Nieto, A.</au><au>Park, Y.C.</au><au>Cheng, P.S.</au><au>Li, W.</au><au>Favis, R.</au><au>Ricci, D.</au><au>Poveda, A.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Effect of BRCA1 and XPG mutations on treatment response to trabectedin and pegylated liposomal doxorubicin in patients with advanced ovarian cancer: exploratory analysis of the phase 3 OVA-301 study</atitle><jtitle>Annals of oncology</jtitle><addtitle>Ann Oncol</addtitle><date>2015-05</date><risdate>2015</risdate><volume>26</volume><issue>5</issue><spage>914</spage><epage>920</epage><pages>914-920</pages><issn>0923-7534</issn><eissn>1569-8041</eissn><abstract>In this exploratory analysis, patients with recurrent ovarian cancer carrying BRCA1mut gene had improved outcomes with trabectedin + PLD treatment compared with PLD alone. Prospective evaluation of BRCA status is likely an important evaluation for DNA-damaging agents and may significantly impact interpretation of clinical studies. XPG may be a biomarker of poor outcome in these patients.
We investigated the association of BRCA1 and XPG mutations with response rate (RR), progression-free survival (PFS) and overall survival (OS) in a subset of patients from a phase 3 clinical trial comparing the efficacy and safety of trabectedin + pegylated liposomal doxorubicin (PLD) versus PLD alone in patients with recurrent ovarian cancer.
A candidate array was designed based on the Breast Cancer Information Core database for BRCA mutation analyses. An exploratory analysis of BRCA1/XPG mutation status was conducted using a two-sided log-rank test and 0.05 significance in germline DNA samples from 264 women with failed first-line platinum-based chemotherapy, randomized (1 : 1) to trabectedin + PLD or PLD alone.
Overall, 41 (16%) of the 264 women had BRCA1mut (trabectedin + PLD: n = 24/135, 18%; PLD: n = 17/129; 13%) and 17 (6%) had XPGmut (trabectedin + PLD: n = 8/135, 6%; PLD: n = 9/129, 7%). A higher RR was observed in BRCA1mut patients (20/41; 49%) versus BRCA1wt patients (62/223; 28%). Within the BRCA1mut group, trabectedin + PLD-treated patients had longer PFS and longer OS than PLD-treated patients (median PFS 13.5 versus 5.5 months, P = 0.0002; median OS 23.8 versus 12.5 months, P = 0.0086), whereas in BRCA1wt patients, OS was not significantly different (median OS: 19.1 versus 19.3 months; P = 0.9377). There were no differences in OS or PFS of patients with XPGmut between the two treatment arms. However, trabectedin + PLD-treated patients with XPGmut had a trend toward shorter PFS (median PFS: 1.9 versus 7.5 months; P = 0.1666) and OS (median OS: 14.5 versus 20.7 months; P = 0.1774) than those with XPGwt.
In this exploratory analysis, patients with recurrent ovarian cancer carrying the BRCA1mut had improved outcomes with trabectedin + PLD treatment compared with PLD alone. Prospective evaluation of BRCA status is likely an important evaluation for DNA-damaging agents and may significantly impact interpretation of clinical studies. XPG may be a biomarker of poor outcome in these patients.</abstract><cop>England</cop><pub>Elsevier Ltd</pub><pmid>25722380</pmid><doi>10.1093/annonc/mdv071</doi><tpages>7</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0923-7534 |
| ispartof | Annals of oncology, 2015-05, Vol.26 (5), p.914-920 |
| issn | 0923-7534 1569-8041 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1819136124 |
| source | MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Alma/SFX Local Collection |
| subjects | Aged Antibiotics, Antineoplastic - adverse effects Antibiotics, Antineoplastic - therapeutic use Antineoplastic Agents, Alkylating - adverse effects Antineoplastic Agents, Alkylating - therapeutic use Antineoplastic Combined Chemotherapy Protocols - adverse effects Antineoplastic Combined Chemotherapy Protocols - therapeutic use BRCA1 BRCA1 Protein - genetics Dioxoles - adverse effects Dioxoles - therapeutic use Disease Progression Disease-Free Survival DNA-Binding Proteins - genetics Doxorubicin - adverse effects Doxorubicin - analogs & derivatives Doxorubicin - therapeutic use Endonucleases - genetics Female Humans Middle Aged Mutation Neoplasm Recurrence, Local Nuclear Proteins - genetics Ovarian Neoplasms - drug therapy Ovarian Neoplasms - genetics Ovarian Neoplasms - mortality Ovarian Neoplasms - pathology pegylated liposomal doxorubicin Pharmacogenetics Polyethylene Glycols - adverse effects Polyethylene Glycols - therapeutic use recurrent ovarian cancer Tetrahydroisoquinolines - adverse effects Tetrahydroisoquinolines - therapeutic use Time Factors Trabectedin Transcription Factors - genetics Treatment Outcome XPG |
| title | Effect of BRCA1 and XPG mutations on treatment response to trabectedin and pegylated liposomal doxorubicin in patients with advanced ovarian cancer: exploratory analysis of the phase 3 OVA-301 study |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-28T00%3A14%3A57IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Effect%20of%20BRCA1%20and%20XPG%20mutations%20on%20treatment%20response%20to%20trabectedin%20and%20pegylated%20liposomal%20doxorubicin%20in%20patients%20with%20advanced%20ovarian%20cancer:%20exploratory%20analysis%20of%20the%20phase%203%20OVA-301%20study&rft.jtitle=Annals%20of%20oncology&rft.au=Monk,%20B.J.&rft.date=2015-05&rft.volume=26&rft.issue=5&rft.spage=914&rft.epage=920&rft.pages=914-920&rft.issn=0923-7534&rft.eissn=1569-8041&rft_id=info:doi/10.1093/annonc/mdv071&rft_dat=%3Cproquest_cross%3E1819136124%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1675167310&rft_id=info:pmid/25722380&rft_els_id=S0923753419315133&rfr_iscdi=true |